Navigation Links
JCI online ahead of print table of contents for May 16, 2014
Date:5/16/2014

Targeting microbial translocation attenuates SIV-mediated inflammation

Patients with HIV often present with signs of immune activation and systemic inflammation, both of which are hypothesized to directly contribute to the development of AIDs in infected individuals. HIV and the related simian immunodeficiency virus (SIV) damage the gut mucosa, leading to translocation of microbes from the intestinal lumen to the general circulation, but it is not clear if microbial translocation is directly responsible for chronic HIV-associated inflammation. In this issue of the Journal of Clinical Investigation, Ivona Pandrea and colleagues at University of Pittsburgh report on a study that validates the microbial translocation hypothesis in SIV-infected pigtail macaques. Sevelamer, a drug that is used to reduce systemic LPS levels in chronic kidney disease patients, was given to SIV-infected animlas to reduce microbial translocation in the gut. Compared to controls, sevelamer-treated animals had decreased systemic LPS and reduced activation of peripheral CD4+ T cells. Importantly, sevelamer treatment dramatically lowered viral titers in the blood and reduced coagulation biomarkers that are associated with the development of cardiovascular co-morbidities. In the accompanying commentary, Liang Shan and Robert Siliciano of John's Hopkins School of Medicine discusse how control of microbial translocation could improve HIV outcomes.

TITLE: Early microbial translocation blockade reduces SIV-mediated inflammation and viral replication

AUTHOR CONTACT: Ivona Pandrea
University of Pittsburgh, Pittsburgh, PA, USA
Phone: 412-624-3242; E-mail: pandrea@pitt.edu

MEDIA CONTACT Allison Hydzik
University of Pittsburgh
Phone: 412-647-9975; E-mail:hydzikam@upmc.edu

View this article at: http://www.jci.org/articles/view/75090

ACCOMPANYING COMMENTARY TITLE: Unraveling the relationship between microbial translocation and systemic immune activation in HIV infection

AUTHOR CONTACT: Robert F. Siliciano
Johns Hopkins Univ Schl Of Medicine, Baltimore, MD, USA
Phone: 410/955-2958; Fax: 410-955-0964; E-mail: rsiliciano@jhmi.edu

View this article at: http://www.jci.org/articles/view/75799


Estrogen underlies sex-specific responses to sildenafil

Heart disease is the leading cause of death in both men and women; however, the disease has a somewhat different clinical presentation in women that has been attributed to estrogen levels. Interestingly, estrogen may underlie sex-specific differences in the efficacy of treatments for heart disease. In the issue of the Journal of Clinical Investigation, Eiki Takimoto and colleagues at Johns Hopkins University School of Medicine investigated the impact of estrogen on the cardioprotective effects of sildenafil, a cGMP-specific phosphodiesterase 5 (PDE5) inhibitor. PDE5 inhibitors block hydrolysis of cGMP, leading to activation of the cGMP-dependent kinase Iα (PKGIα), which prevent pathogenic remodeling of the heart. Using two different murine models of heart disease, Takimoto and colleagues determined that sildenafil ameliorates cardiac pathology in an estrogen-dependent manner in female mice. In female hearts, estrogen maintained constitutive activation of eNOS, leading to tonic synthesis of cGMP; in contrast, male hearts exhibited stress-induced eNOS activation and cGMP synthesis, making sildenafil's effects independent of estrogen. In the accompanying commentary, Elizabeth Murphy and Charles Steenbergen discuss how sex-dependent differences in therapeutic responses should be taken into consider for both treatment options and clinical trial design.

TITLE: PDE5 inhibitor efficacy is estrogen dependent in female heart disease

AUTHOR CONTACT: Eiki Takimoto
Johns Hopkins University School of Medicine, Baltimore, MD, USA
Phone: 410-955-4813; Fax: 410-502-2558; E-mail: etakimo1@jhmi.edu

View this article at: http://www.jci.org/articles/view/70731

ACCOMPANYING COMMENTARY TITLE: Sex, drugs, and trial design: sex influences the heart and drug responses

AUTHOR CONTACT: Elizabeth Murphy
NHLBI, NIH, Bethesda, MD, USA
Phone: 301.496.5828; E-mail: murphy1@nhlbi.nih.gov

View this article at: http://www.jci.org/articles/view/76262


Vaccine-induced cell population inhibits SIV vaccine efficacy

The development of an efficacious HIV vaccine has been challenging. Adjuvants are a critical addition to vaccines to help target and potentiate vaccine-induced immune responses, and several have been used in an attempt to boost HIV-specific immune response with limited success. In this issue of the Journal of Clinical Investigation, Yongjun Sui, Jay Berzofsky, and colleagues at the National Cancer institute examined the effect of different combinations of molecular adjuvants in an SIV vaccine that has previously been shown to provide some protection against rectal SIV challenge in macaques. Adjuvants included components that promote viral protection, improve T cell anti-viral responses, and also inhibit negative immune regulators. The vaccine with the full complement of adjuvants reduced viral load; however, adjuvant alone performed as well as or better than the vaccine. Further investigations revealed that vaccine alone induced higher numbers of myeloid-derived suppressor cells (MDSCs), which suppress the CD8+ T cell-mediated anti-viral response. Additionally, MDSC levels positively correlated with set-point viral loads, indicating that these cells critically affect vaccine efficacy. In the accompanying commentary, Sallie Permar and Herman Staats of Duke University discuss how these findings new finding may benefit future HIV vaccine design.

TITLE: Vaccine-induced myeloid cell population dampens protective immunity to SIV

AUTHOR CONTACT: Yongjun Sui
NCI, Bethesda, MD, USA
Phone: 301-435-8350; E-mail: suiy@mail.nih.gov

Or

Jay A. Berzofsky
NCI, Bethesda, MD, USA
Phone: 301.496.6874; Fax: 301.480.0681; E-mail: berzofsj@mail.nih.gov

View this article at: http://www.jci.org/articles/view/73518

ACCOMPANYING COMMENTARY TITLE: Which comes first: the antigen or the adjuvant?

AUTHOR CONTACT: Sallie Permar
Duke University, Durham, NC, USA
Phone: 919-684-6335; E-mail: sallie.permar@duke.edu

View this article at: http://www.jci.org/articles/view/76263


Enhancing efficacy of the cancer drug cetuximab

Cetuximab is a monoclonal antibody that targets EGFR, which is frequently mutated in various forms of cancer. Currently, cetuximab is FDA approved to treat colorectal cancer (CRC) and head and neck squamous cell carcinoma (HNSCC); however, only 10-20% of patients respond to cetuximab alone. The anti-tumor effects of cetuximab are mediated in part by antibody-dependent cell-mediated cytotoxicity (ADCC) in which the IgG1 constant fragment of cetuximab binds FcγR on NK cells to trigger degranulation. In this issue of the Journal of Clinical Investigation, Holbrook Kohrt and colleagues at Stanford University sought to identify inducible costimulatory molecules on NK cells that enhanced ADCC in an attempt to identify strategies to enhance the efficacy of cetuximab. The athours found that CD137 was upregulated after exposure to cetuximab-bound cancer cells. Using murine models of CRC and HNSCC, Kohrt and colleagues demonstrated that administration of cetuximab followed by an agonistic anti-CD137 antibody had a synergistic effect on NK cell degranulation and tumor-specific cytotoxicity, leading to prolonged survival. In an accompanying commentary, Julie Baumann and Jennifer Grandis of the University of Pittsburg discuss how strategies to enhance secondary immune responses to tumor-targeted antibodies might translate to the clinic.

TITLE: Targeting CD137 enhances the efficacy of cetuximab

AUTHOR CONTACT: Holbrook Kohrt
Stanford University, Stanford, CA, USA
Phone: 650 725-2988; Fax: 650 724-6182; E-mail: kohrt@stanford.edu

View this article at: http://www.jci.org/articles/view/73014

ACCOMPANYING COMMENTARY TITLE: Targeting secondary immune responses to cetuximab: CD137 and the outside story

AUTHOR CONTACT: Julie E. Bauman
Cancer Institute. University of Pittsburgh, Pittsburgh, PA, USA
Phone: 412-623-7833; Fax: 412-648-6579; E-mail: baumanje@upmc.edu

View this article at: http://www.jci.org/articles/view/76264


ALSO IN THIS ISSUE:

HEMATOLOGY TITLE: Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression

AUTHOR CONTACT: Yang Xia
University of Texas-Medical School, Houston, TX, USA
Phone: 713-500-5039; Fax: 713-500-652; E-mail: yang.xia@uth.tmc.edu

View this article at: http://www.jci.org/articles/view/74604

IMMUNOLOGY

TITLE: β-cateninregulated myeloid cell adhesion and migration determine wound healing

AUTHOR CONTACT: Benjamin Alman
Duke University, Durham, NC, USA
Phone: 919.613.6935; Fax: 919.613.6991; E-mail:ben.alman@duke.edu

View this article at: http://www.jci.org/articles/view/62059

ONCOLOGY

TITLE: Synthetic triterpenoid induces 15-PGDH expression and suppresses inflammation-driven colon carcinogenesis

AUTHOR CONTACT: John Letterio
Case Western Reserve University and University Hospitals, Cleveland, OH, USA
Phone: 216-844-3345; Fax: 216-844-5321; E-mail: john.letterio@Uhhospitals.org

View this article at: http://www.jci.org/articles/view/69672

VASCULAR BIOLOGY TITLE: RASA1 Functions in EPHB4 signaling pathway to suppress endothelial mTORC1 activity

AUTHOR CONTACT: Joanne Chan
Hampton University, Hampton, VA, USA
Phone: 757.728.6030; Fax: 757.728.6051; E-mail:joanne.chan@hamptonu.edu

View this article at: http://www.jci.org/articles/view/67084


'/>"/>

Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation
Source:Eurekalert

Related medicine news :

1. New online portal, app provide information on tsunami zones in the Northwest
2. Being Ignored Feels Just as Bad Online
3. Online Tool Could Diagnose Autism Quickly, Developers Say
4. Online Dating Scams Can Take Emotional, Financial Toll
5. Annals of Internal Medicine tip sheet for May 8, 2012, online issue
6. Data release from the Allen Institute for Brain Science expands online atlas offerings
7. Vendors in Nevada, Michigan, & Illinois to be Featured on the PartyPOP.com Online Network
8. Annals of Internal Medicine tip sheet for June 19, 2012, online issue
9. Online weight loss programs that feature successful dieters may help
10. DotComSecrets’ Russell Brunson Is Revealing Online Money Making Secrets in Free Webinars for Students
11. DermaShoppe.com Celebrates Its Second Successful Year in Online Skin Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... , ... “Vintage and Harvest A Cultivation of Christian Love” is the creation ... North Carolina with his wife, Anna Marie. He and his wife are the proud ... also the author of “Shadow and Substance.” , “Love, the agape kind, is seen ...
(Date:3/23/2017)... ... 2017 , ... In 2016 the World Health Organization declared the Zika virus ... Zika-related cases in the Americas within the next year. Lyme disease is one of ... skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other insect borne illnesses are ...
(Date:3/23/2017)... ... March 23, 2017 , ... Demonstrating ... communities, 16 more public health departments have been awarded national accreditation through the ... million people into the expanding network of communities across the nation whose health ...
(Date:3/23/2017)... ... March 23, 2017 , ... The IoT (Internet of Things) is ... making a huge impact on businesses and individual consumers alike. Laboratories can maximize ... have a value anywhere from $4 trillion to $11 trillion dollars by the year ...
(Date:3/23/2017)... , ... March 23, 2017 ... ... financial services firm serving the families and businesses of the Norwalk and ... program. Northern Ohio Recovery Center (N.O.R.A.) is a nonprofit, community-based substance abuse ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... March 24, 2017 ShangPharma, a ... and cost-effective drug development and discovery services, ... biotechnology industry, announced today the intent for ... will be consolidating the Contract Research Organizations ... Shanghai ChemPartner. These entities include ChemPartner Shanghai, ...
(Date:3/24/2017)... India , March 24, 2017 A ... market has been growing rapidly as the global sales of Adcetris ... the growth in the antibody drug conjugates market is driven by ... of cancer and wider therapeutic window offered by ADCs. ... Browse 3 Tables and 94 ...
(Date:3/24/2017)... , March 24, 2017  Eli Lilly and ... plans to invest $850 million in its U.S. ... across its U.S. enterprise, including research laboratories, manufacturing ... are being driven by demand for Lilly products, ... medicines in development targeting cancer, pain, diabetes and ...
Breaking Medicine Technology: